ANTENGENE CORP. DL-0001

Research ANTENGENE CORP. DL-0001 (722) on Bullrun: market cap EUR 212.60M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• Ticker722
• ExchangeF
• CountryChina
• SectorHealthcare
• IndustryBiotechnology
• CurrencyEUR
• Market capEUR 212.60M
• Financial periodFY2024
• RevenueEUR 91.95M
• Revenue growth36.6%
• Net income-EUR 319.25M
• Free cash flow-EUR 382.58M
• Gross margin81.9%

Valuation Snapshot

latest market cap is EUR 212.60M.

About ANTENGENE CORP. DL-0001

Antengene Corporation Limited, a clinical-stage APAC biopharmaceutical company, develops novel oncology therapies in Greater China and internationally. The company's commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse large B-cell lymphoma, and multiple myeloma (MM) in adult patients.

Frequently asked questions

What is ANTENGENE CORP. DL-0001's market cap?

ANTENGENE CORP. DL-0001's market capitalization is EUR 212.60M.

What does ANTENGENE CORP. DL-0001 do?

Antengene Corporation Limited, a clinical-stage APAC biopharmaceutical company, develops novel oncology therapies in Greater China and internationally.